22 June 2009

Flamel Technologies Announces New Feasibility Projects; Technology Access Fee

Announcement
LYON, France – June 22, 2009 – Flamel Technologies, SA (Nasdaq: FLML) today announced that it
has entered into agreements with a leading global healthcare provider to assess the applicability of the
Medusa® platform for controlled release formulations of therapeutic proteins. The Company will
receive technology access fees totaling € 2.5 million pursuant to these agreements, plus full
development costs for the program. A joint press release regarding the agreement is anticipated for
release in mid July.
Stephen H. Willard, Chief Executive Officer of Flamel Technologies, said: “We are very pleased to add
a new partner for multiple molecules using our Medusa technology. We are gratified that our
technology has achieved the recognition which justifies upfront payments as well as the usual license
fees, development fees, milestones, and royalties. We look forward to announcing additional details of
our collaboration in the month to come.”
Flamel Technologies, S.A. is a biopharmaceutical company principally engaged in the development of
two unique polymer-based delivery technologies for medical applications. Micropump® is a controlled
release and taste-masking technology for the oral administration of small molecule drugs. Flamel's
Medusa® technology is designed to deliver controlled-release formulations of therapeutic proteins and
peptides, as well as small molecule drugs.